Flag of the European Union EU Clinical Trials Register Help

Clinical trials for TIA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    182 result(s) found for: TIA. Displaying page 5 of 10.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-001735-49 Sponsor Protocol Number: CTU/2015/174 Start Date*: 2019-07-01
    Sponsor Name:University College London
    Full Title: Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase II/III, non-inferiority trial
    Medical condition: Patients with stroke or other ischaemic brain injury who have antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10002817 Antiphospholipid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-000442-18 Sponsor Protocol Number: ABM/2020/1/00002 Start Date*: 2021-09-24
    Sponsor Name:National Institute of Cardiology
    Full Title: Strategy To Optimize PeriproCeduraL AnticOagulation in Structural Transseptal Interventions (STOP CLOT Trial)
    Medical condition: Mitral regurgitation Atrial fibrilation Periprocedural anticoagulation strategy in patients treated with MitraClip implantation or Left Atrial Appendage Closure. The patients scheduled for Mitr...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10027718 Mitral regurgitation LLT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003698-42 Sponsor Protocol Number: D1250C00012 Start Date*: 2008-11-21
    Sponsor Name:AstraZeneca AB
    Full Title: A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin...
    Medical condition: the prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (AF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003658 Atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) SK (Completed) DE (Completed) HU (Prematurely Ended) ES (Prematurely Ended) FR (Ongoing) DK (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001883-23 Sponsor Protocol Number: 2011CV08 Start Date*: 2011-08-03
    Sponsor Name:University of Dundee
    Full Title: FAST- Febuxostat versus Allopurinol Streamlined Trial A prospective, randomised, open-label, blinded endpoint (PROBE) clinical trial evaluating long term cardiovascular safety of febuxostat in co...
    Medical condition: Chronic symptomatic hyperuricaemic
    Disease: Version SOC Term Classification Code Term Level
    17.0 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) FI (Prematurely Ended) SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002181-38 Sponsor Protocol Number: WARCEF Start Date*: 2004-10-22
    Sponsor Name:NIH-National Institut of Health - NINDS-National Institut of Neurogical Disorders and Stroke
    Full Title: Warfarin versus Aspirin in Reduced Ejection Fraction.
    Medical condition: Patients with left ventricular disfunction with ejection fraction less or equal to 35%.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004817-33 Sponsor Protocol Number: EFC10295 Start Date*: 2008-02-19
    Sponsor Name:sanofi-aventis recherche&développement
    Full Title: A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjuste...
    Medical condition: The subjects who will participate to this clinical trial are not healthy volonteers. They have Permanent, persistent or paroxysmal non-valvular atrial fibrillation that is ECG-documented, with an i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) NL (Completed) ES (Completed) FI (Completed) EE (Completed) GR (Prematurely Ended) DK (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) SK (Completed) PT (Completed) BG (Completed) IT (Prematurely Ended) LT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005972-29 Sponsor Protocol Number: 150-CL-201 Start Date*: 2009-10-01
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in combination with Standard Treatment in Secondary Prevention...
    Medical condition: The investigation will be carried out on subjects with Acute Coronary Syndromes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BE (Completed) DK (Completed) FR (Completed) CZ (Completed) GB (Completed) NL (Completed) SK (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2010-021638-72 Sponsor Protocol Number: HZC113782 Start Date*: 2011-06-09
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: HZC113782: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmo...
    Medical condition: Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) LV (Completed) AT (Completed) DE (Completed) GB (Completed) DK (Prematurely Ended) PL (Completed) GR (Completed) BG (Completed) ES (Completed) IT (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001557-26 Sponsor Protocol Number: CV185-048 Start Date*: 2008-04-29
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: Apixaban Versus Acetylsalicyclic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double Blind Trial ...
    Medical condition: Patients with atrial fibrillation and at least one additional risk factor for stroke who have failed or are unsuitable for vitamin K antagonist therapy.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10042244 Stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) SE (Completed) BE (Completed) DE (Completed) FI (Completed) ES (Completed) DK (Completed) CZ (Completed) AT (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000860-25 Sponsor Protocol Number: CSPP100E2337 Start Date*: 2007-07-27
    Sponsor Name:Novartis Farmacéutica, SA
    Full Title: Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, para determinar si la adición de Aliskiren al tratamiento convencional, en pacientes con diabetes tipo 2 y alto riesg...
    Medical condition: Diabetes tipo 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PT (Prematurely Ended) FR (Completed) FI (Completed) GR (Completed) DE (Completed) DK (Completed) GB (Completed) LT (Completed) BE (Prematurely Ended) HU (Prematurely Ended) NL (Completed) AT (Completed) SE (Prematurely Ended) CZ (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-002147-91 Sponsor Protocol Number: CV185-030 Start Date*: 2007-05-14
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalv...
    Medical condition: ARRHYTHMIA; THROMBOSIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003658 Atrial fibrillation LLT
    9.1 10057613 Thromboembolic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed) BE (Completed) FI (Completed) ES (Completed) DK (Completed) HU (Completed) AT (Completed) CZ (Completed) FR (Completed) DE (Completed) IT (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004338-42 Sponsor Protocol Number: CV185-023 Start Date*: 2006-06-24
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase 2, Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban In Patients with a Recent Acute Coronary Syndrome. Revised Pr...
    Medical condition: ACUTE CORONARY SYNDROMES,NOS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) GB (Completed) ES (Completed) BE (Completed) DE (Completed) DK (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000055-41 Sponsor Protocol Number: CV185-220 Start Date*: 2013-08-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
    Medical condition: Patients with Non-Valvular Atrial Fibrillation with at least one risk factor for stroke and indicated for oral anticoagulant.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004411-29 Sponsor Protocol Number: A3051049 Start Date*: 2006-01-16
    Sponsor Name:
    Full Title: A 12-week, double-blind, placebo-controlled, multicenter study with a 40 week follow-up evaluating the safety and efficacy of Varenicline tartrate 1 mg BID for smoking cessation in subjects with ca...
    Medical condition: Smoking Cessation
    Disease: Version SOC Term Classification Code Term Level
    8.0 10053325 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) CZ (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-012451-18 Sponsor Protocol Number: CRO1202 Start Date*: 2009-09-23
    Sponsor Name:Imperial College London
    Full Title: EUROACTION PLUS: Intensive smoking intervention (Varenicline) during a preventive cardiology programme for patients with established atherosclerotic disease, people at high cariovascular risk and t...
    Medical condition: Current cigarette smokers with coronary or other atherosclerotic disease or people at high risk of developing cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    10053325 Smoking cessation therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-010170-38 Sponsor Protocol Number: CSPP100G2301 Start Date*: 2010-07-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People Aliskiren Prevention Of Later Life Outcomes (APOLLO)
    Medical condition: cardiovacular disease, fonctional hypertension,
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020772 Hypertension LLT
    12.1 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) DE (Completed) IE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002920-10 Sponsor Protocol Number: TRE-1486--0105-I Start Date*: 2016-09-14
    Sponsor Name:Klinikum der Universitaet Muenchen AoeR
    Full Title: TREAT-SVDs: EffecTs of Amlodipine and other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases
    Medical condition: Cerebral small vessel disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2006-005437-38 Sponsor Protocol Number: D1250C00008 Start Date*: 2007-03-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, given as an Extended-release Formulation, in the Prevention of...
    Medical condition: Paroxysmal, persistent or permanent nonvalvular atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003658 Atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) HU (Completed) AT (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001354-42 Sponsor Protocol Number: IAMI-2014 Start Date*: 2014-12-16
    Sponsor Name:Örebro University Hospital
    Full Title: Influenza vaccination After Myocardial Infarction (IAMI trial). A multicenter, prospective, randomized controlled clinical trial based on national angiography and angioplasty registries
    Medical condition: Myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10028596 Myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) LV (Completed) CZ (Completed) NO (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-002277-35 Sponsor Protocol Number: AC16093 Start Date*: 2017-06-01
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: LACunar Intervention (LACI-2) Trial-2: Assessment of safety and efficacy of cilostazol and isosorbide mononitrate to prevent recurrent lacunar stroke and progression of cerebral small vessel disease.
    Medical condition: lacunar (small vessel) ischaemic stroke
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10071043 Basal ganglia stroke PT
    20.0 10029205 - Nervous system disorders 10068644 Brain stem stroke PT
    20.0 10029205 - Nervous system disorders 10023987 Late effects of cerebrovascular disease LLT
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    20.0 10029205 - Nervous system disorders 10042244 Stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 09:40:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA